BUTRANS PATCHES BUPRENORPHINE 30MG 4PATCH

Product Description

Pharmacodynamic properties: Buprenorphine is a partial μ-opioid agonist. It also has antagonistic activity at the kappa-opioid receptor. It is classified as a psychotropic substance under international convention. Opioids can influence the hypothalamic-pituitary-adrenal or –gonadal axes. Some of the changes that can be observed include an increase in serum prolactin and decreases in plasma levels of cortisol and testosterone. Clinical symptoms may manifest due to these hormonal changes. In vitro and animal studies indicate different effects of natural opiates, such as morphine, on components of the immune system; The clinical significance of these findings is unknown. It is unknown whether buprenorphine, a semi-synthetic opiate, has immunological effects similar to morphine. Each SOLORO® 7 buprenorphine transdermal patch provides a constant supply of buprenorphine for up to 7 days. Steady state is reached during the first application on the third day. After removing the patch, buprenorphine concentrations decrease, reducing by approximately 50% in 12 hours (range 10-24 hours). Absorption does not vary significantly between specified application sites. The mean exposure (AUC) at each of the application sites is within approximately +/- 11% of the mean exposure for all four sites. After application of the buprenorphine transdermal patch, the active substance diffuses from the system through the skin. Buprenorphine is approximately 96% bound to plasma proteins. The metabolism of buprenorphine in the skin after patch application is negligible. Buprenorphine is eliminated via hepatic metabolism with subsequent biliary and renal excretion of soluble metabolites. Norbuprenorphine is the only known active metabolite of buprenorphine.